Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Seelos Therapeutics, Inc.    SEEL

SEELOS THERAPEUTICS, INC.

(SEEL)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005) 

share with twitter share with LinkedIn share with facebook
share via e-mail
12/04/2019 | 08:01am EDT

NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Seelos' U.S. Patent number 10,493,023 (Application number 14/889,727) titled: “TREATMENT OF PROTEIN AGGREGATION MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL ADMINISTRATION OF TREHALOSE” (SLS-005).

There are several neurodegenerative conditions related by the commonality of protein aggregations including Sanfilippo syndrome, Oculopharyngeal Muscular Dystrophy (OPMD), Spinocerebellar Ataxia (SCA3), Parkinson’s Disease, Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease, Huntington's disease and Friedreich Ataxia (FA). The USPTO granted Seelos a patent for treating FA with trehalose in July 2019.

Seelos was previously granted orphan indication from the United States Food and Drug Administration for SCA3 and OPMD for trehalose as well as Fast Track designation for OPMD.

About Trehalose

Trehalose is a low molecular weight disaccharide (.342 kDa) that crosses the blood brain barrier, stabilizes proteins, and importantly activates autophagy which is the process that clears material from cells. In several animal models of diseases, associated with abnormal cellular protein aggregation or storage of pathologic material, it has been shown to reduce aggregation of misfolded proteins and reduce accumulation of pathologic material. Trehalose activates autophagy through the activation of Transcription Factor EB (TFEB), a key factor in lysosomal and autophagy gene expression. Activation of TFEB is an emerging therapeutic target for a number of diseases with pathologic accumulation of storage material.

Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com 
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Primary Logo


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SEELOS THERAPEUTICS, INC.
04/08Seelos Therapeutics Provides Q1 2020 Business Update and Pipeline Development..
GL
03/30SEELOS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
03/24Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of..
GL
03/17SEELOS THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
03/16SEELOS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
03/16Seelos Therapeutics Announces Closing of Public Offering of Common Stock
GL
03/12SEELOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Ev..
AQ
03/11Seelos Therapeutics Announces Pricing of $4.5 Million Public Offering of Comm..
GL
03/11Seelos Therapeutics Announces Proposed Public Offering of Common Stock
GL
03/11Seelos Therapeutics Announces European Medicines Agency Guidance to Design an..
GL
More news
Financials (USD)
Sales 2020 -
EBIT 2020 -19,7 M
Net income 2020 -19,7 M
Debt 2020 -
Yield 2020 -
P/E ratio 2020 -0,71x
P/E ratio 2021 -0,79x
Capi. / Sales2020 infx
Capi. / Sales2021 infx
Capitalization 19,7 M
Chart SEELOS THERAPEUTICS, INC.
Duration : Period :
Seelos Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEELOS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 6,00  $
Last Close Price 0,45  $
Spread / Highest target 1 684%
Spread / Average Target 1 238%
Spread / Lowest Target 792%
EPS Revisions
Managers
NameTitle
Raj Mehra Chairman, President, CEO & CFO
Warren W. Wasiewski Chief Medical Officer
Tim Whitaker Head-Research & Development
Jessica Kardish Head-Clinical Operations
Richard W. Pascoe Director
Sector and Competitors
1st jan.Capitalization (M$)
SEELOS THERAPEUTICS, INC.-66.53%20
JOHNSON & JOHNSON-1.79%377 684
ROCHE HOLDING AG0.67%274 005
MERCK & CO., INC-9.95%206 098
NOVARTIS-9.90%192 476
PFIZER, INC.-9.55%191 948